Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Uterine serous carcinoma is an aggressive and uncommon subtype of endometrial cancer, representing approximately 5-10% of all cases but contributing disproportionately to mortality. It primarily affects postmenopausal women and is often diagnosed at an advanced stage, leading to poorer outcomes than more common endometrioid subtypes. The uterine serous carcinoma pipeline analysis by Expert Market Research highlights ongoing development of targeted therapies, immunotherapies, and combination regimens designed to improve survival and long-term disease control.
-
Major companies involved in the uterine serous carcinoma pipeline analysis include Incyte Corporation, Sumitomo Pharma America, Inc., and others.
-
Leading drugs currently in the pipeline include AZD1775, BMS-986463, and others.
-
The pipeline landscape is the increasing integration of molecular profiling and biomarker-driven therapies, such as HER2-targeted agents and immunotherapy combinations, which enable personalised treatment strategies for this aggressive subtype. These precision approaches, informed by distinctive genomic alterations like TP53 and ERBB2, are accelerating novel drug development and clinical trial activity.
Report Coverage
The Uterine Serous Carcinoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into uterine serous carcinoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for uterine serous carcinoma. The uterine serous carcinoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The uterine serous carcinoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with uterine serous carcinoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to uterine serous carcinoma.
Read more about this report - Request a Free Sample
Uterine Serous Carcinoma Pipeline Outlook
Uterine serous carcinoma is an aggressive subtype of endometrial cancer, often diagnosed at an advanced stage and associated with poor prognosis. Standard management typically involves surgery, followed by chemotherapy with carboplatin and paclitaxel, sometimes combined with radiotherapy. Recent advancements in the pipeline are focused on immunotherapy and targeted agents to improve survival outcomes.
Uterine serous carcinoma treatment has recently advanced with the introduction of immunotherapy-based regimens into the clinical pathway. Notably, in June 2024, the FDA approved pembrolizumab (Keytruda) in combination with carboplatin and paclitaxel, followed by single agent pembrolizumab, for adults with primary advanced or recurrent endometrial carcinoma, including serous subtypes. This approval represents a significant therapeutic milestone, offering a new standard-of-care option for patients with this high-risk disease.
Uterine Serous Carcinoma Epidemiology
Uterine serous carcinoma is an uncommon but aggressive subtype of endometrial cancer, accounting for roughly 5-10 % of all endometrial malignancies worldwide. Although exact global incidence figures for this subtype alone are not routinely reported, endometrial cancer overall constitutes a significant and rising share of female cancers globally, with more than 4,70,000 new uterine cancer cases reported in 2021 and increasing incidence trends in many regions. Serous carcinoma contributes disproportionately to mortality despite its lower frequency compared with endometrioid types.
Uterine Serous Carcinoma – Pipeline Therapeutic Assessment
This section of the report covers the analysis of uterine serous carcinoma drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The uterine serous carcinoma pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Peptides
- Gene Therapies
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Uterine Serous Carcinoma Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I covers a major share of the total uterine serous carcinoma clinical trials. Phase I represents approximately 50% of uterine serous carcinoma clinical trials, Phase II 42%, and Phase III 8%. This distribution highlights the strong focus on early-stage development, reflecting active research efforts to expand future treatment options for this aggressive disease.
Uterine Serous Carcinoma Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the uterine serous carcinoma pipeline analysis include monoclonal antibodies, small molecules, peptides, and gene therapies. The uterine serous carcinoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for uterine serous carcinoma. In July 2023, the FDA approved dostarlimab-gxly (Jemperli) with carboplatin and paclitaxel, and as maintenance, for patients with dMMR/MSI-H advanced or recurrent endometrial cancer, a group that includes many cases of serous carcinoma with mismatch repair deficiencies.
Uterine Serous Carcinoma Clinical Trials – Key Players
The EMR report for the uterine serous carcinoma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed uterine serous carcinoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in uterine serous carcinoma clinical trials:
- Bristol-Myers Squibb
- AbbVie
- Volastra Therapeutics, Inc.
- Seagen (a wholly owned subsidiary of Pfizer)
- Incyte Corporation
- Sumitomo Pharma America, Inc.
- Genmab
- DualityBio Inc.
- BioNTech SE
- Astellas Pharma Inc
Uterine Serous Carcinoma – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for uterine serous carcinoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of uterine serous carcinoma drug candidates.
Biological: DB-1303/BNT323
DB-1303/BNT323 is an antibody-drug conjugate (ADC) candidate that links a HER2-targeting antibody with a cytotoxic payload to selectively deliver chemotherapy into HER2-expressing cancer cells, causing targeted tumor cell death. It has shown encouraging early results in Phase 1/2 trials and received FDA Breakthrough Therapy and Fast Track designations in advanced endometrial cancer. Developed through a collaboration between BioNTech SE and Duality Biologics, this next-generation HER2 ADC aims to improve outcomes in advanced solid tumors with HER2 expression.
Drug: SMP3124LP
SMP3124LP is a liposomal formulation of a checkpoint kinase 1 (Chk1) inhibitor, designed to enhance antitumor activity by impairing DNA repair in cancer cells and inducing apoptosis. Encapsulating the inhibitor within liposomes may improve delivery and reduce off-target toxicity. It is being investigated in Phase 1/2 clinical trials for advanced solid tumors, including difficult-to-treat cancers. The program is sponsored by Sumitomo Pharma America, Inc., reflecting its ongoing commitment to novel oncology treatments.
Drug: VLS-1488
VLS-1488 is an oral small molecule inhibitor of KIF18A, a mitotic kinesin critical for chromosome segregation in dividing cells. By inhibiting KIF18A, VLS-1488 disrupts tumor cell division and may induce cell death, especially in cancers with high chromosomal instability. It is in Phase 1/2 trials for advanced solid tumors, demonstrating safety and preliminary efficacy. The candidate is developed by Volastra Therapeutics, a biotechnology company focused on therapies targeting chromosomal instability.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Uterine Serous Carcinoma Pipeline Insight Report
- Which companies/institutions are leading the uterine serous carcinoma drug development?
- Which company is leading the uterine serous carcinoma pipeline development activities?
- What is the current uterine serous carcinoma commercial assessment?
- What are the opportunities and challenges present in the uterine serous carcinoma pipeline landscape?
- What is the efficacy and safety profile of uterine serous carcinoma pipeline drugs?
- Which company is conducting major trials for uterine serous carcinoma drugs?
- Which companies/institutions are involved in uterine serous carcinoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in uterine serous carcinoma?
Reasons To Buy This Report
The Uterine Serous Carcinoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for uterine serous carcinoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into uterine serous carcinoma collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Uterine Fibroid Treatment Devices Market
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share